ACM
MED icon

AlphaCrest Capital Management’s Medifast MED Stock Holding History

AlphaCrest Capital Management’s Portfolio MED Stock Details MED Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-8,578
Closed -$930K – 689
2022
Q3 		$930K Buy
+8,578
New +$1.23M 0.06% 660

Other funds holding MED

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

AlphaCrest Capital Management's MED Position: Q4 2022 in Review

AlphaCrest Capital Management sold out of Medifast (MED) in Q4 2022, closing a stake of 8,578 shares — an estimated $930K sold.

AlphaCrest Capital Management first reported a position in MED in Q3 2022 and held it in 1 quarter. The position peaked at $930K in Q3 2022. 279 funds tracked by Wall St. Rank hold MED as of Q4 2022.

  • AlphaCrest Capital Management reported no remaining Medifast position as of Q4 2022 after selling out during the quarter.
  • AlphaCrest Capital Management sold 8,578 Medifast shares in Q4 2022, an estimated $930K.
  • AlphaCrest Capital Management first reported a position in Medifast in Q3 2022 and held it in 1 quarter.
  • AlphaCrest Capital Management's Medifast position peaked at $930K in Q3 2022.
  • 279 funds tracked by Wall St. Rank held Medifast as of Q4 2022.

Based on AlphaCrest Capital Management's 13F filing for Q4 2022.